Blinatumomab-based salvage in relapsed/refractory B-cell acute lymphoblastic leukemia: "real world" experience from a single-centre in India

Pediatric Hematology Oncology Journal Pub Date : 2025-03-12 DOI:10.1016/j.phoj.2025.03.002

Vaibhav Chadha, Garima Nirmal, Goutomi Chatterjee, Subhasish Paul, Gurpreet Singh, Nikhil Gupta, Gaurav Kharya

{"title":"Blinatumomab-based salvage in relapsed/refractory B-cell acute lymphoblastic leukemia: \"real world\" experience from a single-centre in India","authors":"Vaibhav Chadha, Garima Nirmal, Goutomi Chatterjee, Subhasish Paul, Gurpreet Singh, Nikhil Gupta, Gaurav Kharya","doi":"10.1016/j.phoj.2025.03.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Blinatumomab is effective in achieving disease remission in children with CD-19 positive relapsed/refractory (R/R) B-lineage acute lymphoblastic leukemia (B-ALL).</div></div><div><h3>Case series</h3><div>Blinatumomab was administered to nine patients with R/R B-ALL, of which 8 (88 %) were not in remission post-salvage chemotherapy. Seven of eight (87.5 %) patients attained morphological remission, and 5/8 (62.5 %) had measurable residual disease response following the first cycle. Three received a second cycle; 2 were non-responsive, and 1 had progressive disease during therapy. Cytokine release syndrome Grade 3 was seen in 2/9 (22 %) patients. Seven (78 %) underwent hematopoietic stem cell transplant. At a median follow-up of 650 days, the overall survival and progression-free survival of the cohort was 55.6 % (±16.6).</div></div><div><h3>Conclusion</h3><div>Our case series emphasizes the feasibility and ease of administration of blinatumomab with minimal toxicity, and efficacy similar to international reports in a resource-limited setting.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"10 2","pages":"Article 100447"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology Oncology Journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468124525000087","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Blinatumomab is effective in achieving disease remission in children with CD-19 positive relapsed/refractory (R/R) B-lineage acute lymphoblastic leukemia (B-ALL).

Case series

Blinatumomab was administered to nine patients with R/R B-ALL, of which 8 (88 %) were not in remission post-salvage chemotherapy. Seven of eight (87.5 %) patients attained morphological remission, and 5/8 (62.5 %) had measurable residual disease response following the first cycle. Three received a second cycle; 2 were non-responsive, and 1 had progressive disease during therapy. Cytokine release syndrome Grade 3 was seen in 2/9 (22 %) patients. Seven (78 %) underwent hematopoietic stem cell transplant. At a median follow-up of 650 days, the overall survival and progression-free survival of the cohort was 55.6 % (±16.6).

Conclusion

Our case series emphasizes the feasibility and ease of administration of blinatumomab with minimal toxicity, and efficacy similar to international reports in a resource-limited setting.

查看原文本刊更多论文

基于布利纳单抗的复发/难治性b细胞急性淋巴母细胞白血病抢救：来自印度单一中心的“真实世界”经验

背景：blinatumumab可有效缓解CD-19阳性复发/难治性（R/R） b系急性淋巴细胞白血病（B-ALL）患儿的疾病。9例R/R B-ALL患者使用blinatumumab，其中8例（88%）在挽救性化疗后未缓解。8例患者中有7例（87.5%）达到形态缓解，5/8例（62.5%）在第一个周期后有可测量的残留疾病反应。其中三人接受了第二轮治疗；2例无反应，1例在治疗期间病情进展。细胞因子释放综合征3级见于2/9（22%）的患者。7例（78%）接受了造血干细胞移植。在中位650天的随访中，该队列的总生存率和无进展生存率为55.6%（±16.6%）。结论：我们的病例系列强调了在资源有限的情况下使用blinatumomab的可行性和易用性，毒性最小，疗效与国际报道相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Hematology Oncology Journal

CiteScore

1.00

自引率

0.00%

发文量